Granules India Share Price

Granules India is a Hyderabad-headquartered pharmaceutical company with four decades of proven performance and a strong international presence.

The company works in partnership with global pharmaceutical leaders by producing API (active pharmaceutical ingredient), PFI (pharmaceutical formulation intermediate) and FD (finished dosages) through manufacturing excellence, process innovation and regulatory expertise. The company also distributes its own labelled products to various global markets.

Granules India started its journey in 1984 as Triton Laboratories by producing paracetamol API at its Hyderabad facility. Later, in 1991, the company was incorporated as Granules India Pvt. Ltd.

Spanning across Hyderabad, Visakhapatnam and Virginia, the company now has eight state-of-the-art manufacturing facilities.

Two are dedicated API and PFI manufacturing sites at Bonthapally and Jeedimetla in Hyderabad. In 2013, through the acquisition of Auctus Pharmaceuticals, the company took over a multi-product API manufacturing facility at Visakhapatnam (with two units there) and an intermediary manufacturing facility at Bonthapally.

Gagillapur unit in Hyderabad is one of the largest single-unit manufacturing sites for PFIs and finished dosages. Granules has also set up a formulation R&D (research and development) and manufacturing facility in Virginia, USA, to develop and commercialise oral solid dosages in the US.

In 1995, Granules India became a listed company, following an initial public offering (IPO). As of January 3, 2024, the company had a market capitalization of over ₹10,000 crore, with the share price having risen over 16% in the past three years.

Business operations

Granules India specialises in the production of API, PFI and FD, which are marketed across key markets in North America, Europe, India and Latin America. The company also entered the over-the-counter business in the US in 2015 through its label Granules Consumer Healthcare.

Finished Dosages (FD):

This segment is the biggest revenue contributor for Granules India, accounting for 50% of the overall turnover. The company’s current product line-up consists of caplets, tablets, and press-fit capsules, in bulk, blister packs, and bottles. These products are manufactured at the company’s Gagillapur facility and are distributed in over 80 countries worldwide.

Active Pharmaceutical Ingredients (API):

Granules is a leading producer and supplier of paracetamol, metformin, guaifenesin and methocarbamol APIs. Almost 30% of its revenue came from the API business in 2022-23. The company is renowned for efficient and cost-effective manufacturing operations.

Pharmaceutical Formulation Intermediates (PFI):

Granules is a leading global manufacturer of PFI with a batch processing capacity of 6 tonnes. The company’s Jeedimetla and Gagillapur facilities enable it to process intermediates and transform them into final doses using compression techniques. This segment contributed 20% to the company’s revenue in FY23.

Financial highlights

The company reported significant improvement in its performance in 2022-23 over the previous year. This growth can be attributed to the increase in sales of API and FD products, particularly in key markets such as the US and EU. In 2022-23, the company’s revenue jumped 20% to ₹4,512 crore compared with ₹3,765 crore in FY22. EBITDA jumped 27% to ₹913.8 crore in FY23 from ₹722.2 crore in FY22. Profit after tax (PAT) rose 25% to ₹516.6 crore in FY23 as against ₹412.7 crore in FY22. The company’s capital expenditure for the year amounted to ₹410.6 crore.